Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

Tenpoint Therapeutics submitted a Marketing Authorisation Application (MAA) to the UK’s MHRA for review of YUVEZZI™ to treat presbyopia. The filing is a positive regulatory milestone, though it does not by itself indicate approval timing or commercial impact.

Analysis

Tenpoint Therapeutics submitted a Marketing Authorisation Application (MAA) to the UK’s MHRA for review of YUVEZZI™ to treat presbyopia. The filing is a positive regulatory milestone, though it does not by itself indicate approval timing or commercial impact.